Cancer Diagnostics and Immunotherapeutics
Note
Indigenisation of CAR-T cell therapy reduces treatment costs, and early diagnostics directly determine five-year survival outcomes across India's high-burden cancers. Detection technologies include liquid biopsy, PET-CT imaging, biomarker-based screening, and next-generation sequencing used within India's National Cancer Grid. Immunotherapeutic modalities include PD-1/PD-L1 checkpoint inhibitors and monoclonal antibodies developed under Department of Biotechnology mission programmes. Clinical trial approval for biologics is governed by Schedule Y of the Drugs and Cosmetics Act. CAR-T development links oncology innovation to the goal of affordable domestic biologics.
In the news
Questions on this topic
Consider the following statements regarding CAR-T cell therapy, its manufacturing process, and characteristic adverse events:
- In CAR-T cell therapy, T cells are extracted from the patient, genetically re-engineered to target aberrant immune cells, and then reinfused into the same patient — making it an autologous, personalised immunotherapy.
- Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are well-recognised adverse events associated with CAR-T cell therapy, with ICANS manifesting as a neurological complication.
- A compressed CAR-T manufacturing process — which shortens cell production time significantly compared with the conventional protocol — has been associated with infusion of cells in a more mature, fully differentiated state, reducing the risk of hyperinflammatory responses.
Which of the statements given above is/are correct?
Explanation
Statement 1 is correct. CAR-T (Chimeric Antigen Receptor T-cell) therapy is an autologous immunotherapy: the patient's own T cells are harvested, genetically engineered in the laboratory to express chimeric antigen receptors that recognise and destroy specific target cells (in autoimmune applications, rogue immune cells rather than cancer cells), and then reinfused into the same patient. Statement 2 is correct. CRS (systemic inflammation driven by massive cytokine release following T-cell expansion) and ICANS (immune effector cell-associated neurotoxicity syndrome, a potentially severe neurological complication) are both established, named toxicities in the CAR-T adverse-event profile. Statement 3 is incorrect in its characterisation. A compressed manufacturing process — one that cuts production time from the conventional standard of more than ten days to fewer than two — delivers cells in an immature, not a mature or fully differentiated, form. It is precisely this cellular immaturity that researchers believe triggers a severe inflammatory response as the immature cells expand rapidly inside the patient's body. Hyperinflammatory events such as IEC-HS (immune effector cell-associated haemophagocytic lymphohistiocytosis and related syndromes) have been linked to this compressed process, not to a conventional longer process.
Your record on this topic
Sign in to see how many of these you have answered, which ones you got wrong, and to practise this topic on its own.
Sign in →Under the same heading
- Common Clinical Conditions and Evidence-Based Care Guidelines
- Counterfeit drug rackets
- Drug regulation and approval
- Infectious disease outbreaks
- Mental health policy
- National Medical Commission and Medical Education Regulation
- Primary education
- Skill Development and Vocational Training Ecosystem
- Stroke Burden and Acute Stroke-Care Delivery